GenVec creates novel vectors for vaccine development

GenVec, Inc. (Nasdaq: GNVC) announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.

"Identifying new adenoviruses capable of generating potent immune responses contributes to GenVec's leadership in vectored vaccine development," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research. "These new vectors could have major advantages for vaccines where it is critical to achieve potent stimulation of the immune system."  

SOURCE GenVec, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine